share_log

Ladenburg Thalmann Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $21

Ladenburg Thalmann Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $21

拉登堡·塔尔曼以买入评级启动对Nuvectis Pharma的报道,宣布目标股价为21美元
Benzinga Real-time News ·  2022/07/13 08:38

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Buy rating and announces Price Target of $21.

拉登堡·塔尔曼分析师艾登·侯赛诺夫以买入评级开始对Nuvectis Pharma(纳斯达克股票代码:NVCT)进行报道,并宣布目标股价为21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发